Placebo Controled Clinical Trial Using Topiramate To Treat Posttraumatic Stress Disorder (PTSD) Patients.
Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
The study is 12-week randomized placebo controlled trial compared to topiramate to treat
patients with posttraumatic stress disorder, according to DSM-IV criteria.
Patients will receive topiramate or placebo, the dose will start with 25 mg/day and every
week 25mg will be increment according to patients tolerance to side effects.
Patients will be evaluated by blind raters using Clinician-Administered PTSD Scale (CAPS),
Beck Depression Inventory (BDI) , Beck Anxiety Inventory (BAI), 36-Item Short Form Health
Survey (SF-36), Social Adjustment Scale (SAS).
the outcomes will be improvement on Posttraumatic Stress Disorder (PTSD), Depression,
Anxiety, quality of life and social adjustment scale according to scales above.
Phase:
Phase 4
Details
Lead Sponsor:
Federal University of São Paulo
Collaborator:
Fundação de Amparo à Pesquisa do Estado de São Paulo